Let us help you navigate
your prostate cancer concerns.
PCSANM members are survivors
who are here to answer your questions.
Due to COVID-19, PCSANM has closed its office and suspended until further notice all regularly scheduled, in-person Saturday support group meetings. If you need support, please call for a consultation by phone or email for information on web-based support group meetings.
Charitable giving tends to plunge during trying times.
You can help. Simply click the Donate button on this page.
The next annual conference is scheduled for November 7, 2020
in Albuquerque, NM.
Our bi-weekly meetings providing support and educational information are suspended until further notice due to coronavirus.
Free Library & Resources
Approximately 1 in 7 men will get prostate cancer.
PCSANM helps all interested individuals and their families who are involved in coping with this disease.
- Publications and other reading materials on a wide variety of prostate cancer subjects
- Free one-on-one consultations for those diagnosed with prostate cancer and those dealing with the diagnosis of a loved one
- A list of survivors willing to discuss their treatment experience and side effects
- Bi-monthly support meetings including presentations by medical professionals expert in prostate cancer and related topics
- Outreach activities at conferences and health fairs
- Educational presentations to organizations
- Vouchers for free PSA tests for those who have no medical insurance, no primary care physician, or are experiencing troubling symptoms
We offer education, information, and support and will share our experiences with prostate cancer treatments and side effects.
Data confirm decades-old hypothesis that metastatic disease hijacks tissue-specific developmental programs.
Expanded research program and revolutionary, inexpensive, non-invasive test to assess genetic risk of prostate cancer is now in development
Largest-ever study of prostate cancer genomics in black men identifies potential targets for precision therapies
Black patients could also benefit from recently approved PARP therapies.